NCT02179177View on ClinicalTrials.gov

Apixaban in Patients With Sickle Cell Disease

PHASE3TerminatedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 3, 2017

Study Completion Date

September 3, 2017

Conditions

Vaso-occlusive CrisisReduction in HospitalizationsSickle Cell Disease

Interventions

DRUG

Apixaban

Drug is taken by mouth twice a day for 6 months

DRUG

Placebo

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Nirmish Shah

OTHER

NCT02179177 - Apixaban in Patients With Sickle Cell Disease | Biotech Hunter | Biotech Hunter